CoChat
Sign Up
Cited by 38Bacteriophages and microbial interactionsVirus-based gene therapy researchRNA Interference and Gene Delivery

Bacteriophage-Mediated Cancer Gene Therapy

Open access
Petrov, Gleb, Dymova, Maya, Richter, Vladimir·2022·International Journal of Molecular Sciences
DOI 10.3390/ijms232214245PMC PMC9697857
Open this paper in CoChat — free accountOpen PDF

Abstract

Bacteriophages have long been considered only as infectious agents that affect bacterial hosts. However, recent studies provide compelling evidence that these viruses are able to successfully interact with eukaryotic cells at the levels of the binding, entry and expression of their own genes. Currently, bacteriophages are widely used in various areas of biotechnology and medicine, but the most intriguing of them is cancer therapy. There are increasing studies confirming the efficacy and safety of using phage-based vectors as a systemic delivery vehicle of therapeutic genes and drugs in cancer therapy. Engineered bacteriophages, as well as eukaryotic viruses, demonstrate a much greater efficiency of transgene delivery and expression in cancer cells compared to non-viral gene transfer methods. At the same time, phage-based vectors, in contrast to eukaryotic viruses-based vectors, have no natural tropism to mammalian cells and, as a result, provide more selective delivery of therapeutic cargos to target cells. Moreover, numerous data indicate the presence of more complex molecular mechanisms of interaction between bacteriophages and eukaryotic cells, the further study of which is necessary both for the development of gene therapy methods and for understanding the cancer nature. In this review, we summarize the key results of research into aspects of phage–eukaryotic cell interaction and, in particular, the use of phage-based vectors for highly selective and effective systemic cancer gene therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms232214245

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Advanced synthetic biology approaches enable incorporation of complex genetic circuits and therapeutic genes into phages.

    “Advanced synthetic biology approaches enable the incorporation of complex genetic circuits and therapeutic genes [15,76,87–89]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [87]

    Section 4.2 describes insertion of a therapeutic-gene cassette into an M13 phage-based vector, and the Conclusions discuss engineered phages delivering therapeutic transgenes. These passages support incorporation of therapeutic genes, but the paper does not establish that complex genetic circuits can be incorporated into phages. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 105

  1. [1]Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J. Clin. 2021 71 209 249 10.3322/caac.21660 33538338 · DOI · Paper page
  2. [2]Yamamoto M. Curiel D.T. Cancer gene therapy Technol. Cancer Res. Treat. 2005 4 315 330 10.1177/153303460500400402 16029053 · DOI
  3. [3]Bouard D. Alazard-Dany D. Cosset F.L. Viral vectors: From virology to transgene expression Br. J. Pharmacol. 2009 157 153 165 10.1038/bjp.2008.349 18776913 PMC2629647 · DOI
  4. [4]Waehler R. Russell S.J. Curiel D.T. Engineering targeted viral vectors for gene therapy Nat. Rev. Genet. 2007 8 573 587 10.1038/nrg2141 17607305 PMC7097627 · DOI
  5. [5]Hosseinidoust Z. Phage-Mediated Gene Therapy Curr. Gene Ther. 2017 17 120 126 10.2174/1566523217666170510151940 28494733 · DOI
  6. [6]Hajitou A. Targeted systemic gene therapy and molecular imaging of cancer contribution of the vascular-targeted AAVP vector Adv. Genet. 2010 69 65 82 10.1016/S0065-2660(10)69008-6 20807602 · DOI
  7. [7]Bao Q. Li X. Han G. Zhu Y. Mao C. Yang M. Phage-based vaccines Adv. Drug Deliv. Rev. 2019 145 40 56 10.1016/j.addr.2018.12.013 30594492 · DOI
  8. [8]Zhang J. Li D. Zhang R. Peng R. Li J. Delivery of microRNA-21-sponge and pre-microRNA-122 by MS2 virus-like particles to therapeutically target hepatocellular carcinoma cells Exp. Biol. Med. 2021 246 2463 2472 10.1177/15353702211035689 PMC8649937 34644206 · DOI
  9. [9]Chang L. Wang G. Jia T. Zhang L. Li Y. Han Y. Zhang K. Lin G. Zhang R. Li J. Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma Oncotarget 2016 7 23988 24004 10.18632/oncotarget.8115 26992211 PMC5029679 · DOI
  10. [10]Sánchez-Sánchez L. Tapia-Moreno A. Juarez-Moreno K. Patterson D.P. Cadena-Nava R.D. Douglas T. Vazquez-Duhalt R. Design of a VLP-nanovehicle for CYP450 enzymatic activity delivery J. Nanobiotechnol. 2015 13 66 10.1186/s12951-015-0127-z PMC4599659 26452461 · DOI
  11. [11]Gandra N. Abbineni G. Qu X. Huai Y. Wang L. Mao C. Bacteriophage bionanowire as a carrier for both cancer-targeting peptides and photosensitizers and its use in selective cancer cell killing by photodynamic therapy Small 2013 9 215 221 10.1002/smll.201202090 23047655 PMC3703240 · DOI
  12. [12]Hatfull G.F. Hendrix R.W. Bacteriophages and their genomes Curr. Opin. Virol. 2011 1 298 303 10.1016/j.coviro.2011.06.009 22034588 PMC3199584 · DOI
  13. [13]Catalao M.J. Gil F. Moniz-Pereira J. Sao-Jose C. Pimentel M. Diversity in bacterial lysis systems: Bacteriophages show the way FEMS Microbiol. Rev. 2013 37 554 571 10.1111/1574-6976.12006 23043507 · DOI
  14. [14]Koskella B. Brockhurst M.A. Bacteria-phage coevolution as a driver of ecological and evolutionary processes in microbial communities FEMS Microbiol. Rev. 2014 38 916 931 10.1111/1574-6976.12072 24617569 PMC4257071 · DOI
  15. [15]Gibb B. Hyman P. Schneider C.L. The Many Applications of Engineered Bacteriophages-An Overview Pharmaceuticals 2021 14 634 10.3390/ph14070634 34208847 PMC8308837 · DOI
  16. [16]Lanigan T.M. Kopera H.C. Saunders T.L. Principles of Genetic Engineering Genes 2020 11 291 10.3390/genes11030291 32164255 PMC7140808 · DOI
  17. [17]Tavares P. The Bacteriophage Head-to-Tail Interface Subcell. Biochem. 2018 88 305 328 10.1007/978-981-10-8456-0_14 29900503 · DOI
  18. [18]Kostyuchenko V.A. Leiman P.G. Chipman P.R. Kanamaru S. van Raaij M.J. Arisaka F. Mesyanzhinov V.V. Rossmann M.G. Three-dimensional structure of bacteriophage T4 baseplate Nat. Struct. Mol. Biol. 2003 10 688 693 10.1038/nsb970 12923574 · DOI
  19. [19]Boeckaerts D. Stock M. Criel B. Gerstmans H. De Baets B. Briers Y. Predicting bacteriophage hosts based on sequences of annotated receptor-binding proteins Sci. Rep. 2021 11 1467 10.1038/s41598-021-81063-4 33446856 PMC7809048 · DOI
  20. [20]Straus S.K. Bo H.E. Filamentous Bacteriophage Proteins and Assembly Subcell. Biochem. 2018 88 261 279 10.1007/978-981-10-8456-0_12 29900501 · DOI
  21. [21]Stone E. Campbell K. Grant I. McAuliffe O. Understanding and Exploiting Phage-Host Interactions Viruses 2019 11 567 10.3390/v11060567 31216787 PMC6630733 · DOI
  22. [22]Leiman P.G. Shneider M.M. Contractile tail machines of bacteriophages Adv. Exp. Med. Biol. 2012 726 93 114 10.1007/978-1-4614-0980-9_5 22297511 · DOI
  23. [23]Dams D. Brondsted L. Drulis-Kawa Z. Briers Y. Engineering of receptor-binding proteins in bacteriophages and phage tail-like bacteriocins Biochem. Soc. Trans. 2019 47 449 460 10.1042/BST20180172 30783013 · DOI
  24. [24]Sciara G. Bebeacua C. Bron P. Tremblay D. Ortiz-Lombardia M. Lichière J. van Heel M. Campanacci V. Moineau S. Cambillau C. Structure of lactococcal phage p2 baseplate and its mechanism of activation Proc. Natl. Acad. Sci. USA 2010 107 6852 6857 10.1073/pnas.1000232107 20351260 PMC2872406 · DOI
  25. [25]Szermer-Olearnik B. Drab M. Mąkosa M. Zembala M. Barbasz J. Dąbrowska K. Boratyński J. Aggregation/dispersion transitions of T4 phage triggered by environmental ion availability J. Nanobiotechnol. 2017 15 32 10.1186/s12951-017-0266-5 28438164 PMC5404661 · DOI
  26. [26]Maghsoodi A. Chatterjee A. Andricioaei I. Perkins N.C. How the phage T4 injection machinery works including energetics, forces, and dynamic pathway Proc. Natl. Acad. Sci. USA 2019 116 25097 25105 10.1073/pnas.1909298116 31767752 PMC6911207 · DOI
  27. [27]Hay I.D. Lithgow T. Filamentous phages: Masters of a microbial sharing economy EMBO Rep. 2019 20 e47427 10.15252/embr.201847427 30952693 PMC6549030 · DOI
  28. [28]Olszak T. Latka A. Roszniowski B. Valvano M.A. Drulis-Kawa Z. Phage Life Cycles Behind Bacterial Biodiversity Curr. Med. Chem. 2017 24 3987 4001 10.2174/0929867324666170413100136 28412903 · DOI
  29. [29]Lobocka M. Dabrowska K. Gorski A. Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future BioDrugs 2021 35 255 280 10.1007/s40259-021-00480-z 33881767 PMC8084836 · DOI
  30. [30]Lang L.H. FDA approves use of bacteriophages to be added to meat and poultry products Gastroenterology 2006 131 1370 10.1053/j.gastro.2006.10.012 17067600 · DOI
  31. [31]Svircev A. Roach D. Castle A. Framing the Future with Bacteriophages in Agriculture Viruses 2018 10 218 10.3390/v10050218 29693561 PMC5977211 · DOI
  32. [32]Schofield D.A. Sharp N.J. Westwater C. Phage-based platforms for the clinical detection of human bacterial pathogens Bacteriophage 2012 2 105 283 10.4161/bact.19274 23050221 PMC3442824 · DOI
  33. [33]Campbell A. The future of bacteriophage biology Nat. Rev. Genet. 2003 4 471 477 10.1038/nrg1089 12776216 PMC7097159 · DOI
  34. [34]Podlacha M. Grabowski Ł. Kosznik-Kawśnicka K. Zdrojewska K. Stasiłojć M. Węgrzyn G. Węgrzyn A. Interactions of Bacteriophages with Animal and Human Organisms-Safety Issues in the Light of Phage Therapy Int. J. Mol. Sci. 2021 22 8937 10.3390/ijms22168937 34445641 PMC8396182 · DOI
  35. [35]Bakhshinejad B. Sadeghizadeh M. Bacteriophages as vehicles for gene delivery into mammalian cells: Prospects and problems Expert Opin. Drug Deliv. 2014 11 1561 1574 10.1517/17425247.2014.927437 24955860 · DOI
  36. [36]Kurzepa A. Dabrowska K. Skaradzinski G. Gorski A. Bacteriophage interactions with phagocytes and their potential significance in experimental therapy Clin. Exp. Med. 2009 9 93 100 10.1007/s10238-008-0027-8 19184327 PMC7088290 · DOI
  37. [37]Merril C.R. Friedman T.B. Attallah A.F.M. Geier M.R. Krell K. Yarkin R. Isolation of bacteriophages from commercial sera In Vitr. Cell. Dev. Biol. 1972 8 91 93 10.1007/BF02615965 4567658 · DOI
  38. [38]Geier M.R. Merril C.R. Lambda phage transcription in human fibroblasts Virology 1972 47 638 643 10.1016/0042-6822(72)90553-3 4551993 · DOI
  39. [39]Larocca D. Witte A. Johnson W. Pierce G.F. Baird A. Targeting bacteriophage to mammalian cell surface receptors for gene delivery Hum. Gene Ther. 1998 9 2393 2399 10.1089/hum.1998.9.16-2393 9829538 · DOI
  40. [40]Gorski A. Dabrowska K. Switala-Jeleń K. Nowaczyk M. Weber-Dabrowska B. Boratynski J. Wietrzyk J. Opolski A. New insights into the possible role of bacteriophages in host defense and disease Med. Immunol. 2003 2 2 10.1186/1476-9433-2-2 12625836 PMC151275 · DOI
  41. [41]Dabrowska K. Opolski A. Wietrzyk J. Switala-Jelen K. Boratynski J. Nasulewicz A. Lipinska L. Chybicka A. Kujawa M. Zabel M. Antitumor activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of beta3 integrin signaling pathway Acta Virol. 2004 48 241 248 15745047
  42. [43]Lehti T.A. Pajunen M.I. Skog M.S. Finne J. Internalization of a polysialic acid-binding Escherichia coli bacteriophage into eukaryotic neuroblastoma cells Nat. Commun. 2017 8 1915 10.1038/s41467-017-02057-3 29203765 PMC5715158 · DOI
  43. [44]Nguyen S. Baker K. Padman B.S. Patwa R. Dunstan R.A. Weston T.A. Schlosser S. Bailey B. Lithgow T. Lazarou M. Bacteriophage Transcytosis Provides a Mechanism To Cross Epithelial Cell Layers mBio 2017 8 e01874-17 10.1128/mBio.01874-17 29162715 PMC5698557 · DOI
  44. [45]Tian Y. Wu M. Liu X. Liu Z. Zhou Q. Niu Z. Huang Y. Probing the endocytic pathways of the filamentous bacteriophage in live cells using ratiometric pH fluorescent indicator Adv. Healthc. Mater. 2015 4 413 419 10.1002/adhm.201400508 25308797 · DOI
  45. [46]Sweere J.M. Van Belleghem J.D. Ishak H. Bach M.S. Popescu M. Sunkari V. Kaber G. Manasherob R. Suh G.A. Cao X. Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection Science 2019 363 10.1126/science.aat9691 PMC6656896 30923196 · DOI
  46. [47]Bichet M.C. Chin W.H. Richards W. Lin Y.-W. Avellaneda-Franco L. Hernandez C.A. Oddo A. Chernyavskiy O. Hilsenstein V. Neild A. Bacteriophage uptake by mammalian cell layers represents a potential sink that may impact phage therapy iScience 2021 24 102287 10.1016/j.isci.2021.102287 33855278 PMC8024918 · DOI
  47. [48]Bodner K. Melkonian A.L. Covert M.W. The Enemy of My Enemy: New Insights Regarding Bacteriophage-Mammalian Cell Interactions Trends Microbiol. 2021 29 528 541 10.1016/j.tim.2020.10.014 33243546 · DOI
  48. [50]Gogokhia L. Buhrke K. Bell R. Hoffman B. Brown D.G. Hanke-Gogokhia C. Ajami N.J. Wong M.C. Ghazaryan A. Valentine J.F. Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis Cell Host Microbe 2019 25 285 299 10.1016/j.chom.2019.01.008 30763538 PMC6885004 · DOI
  49. [51]Hulo C. Masson P. de Castro E. Auchincloss A.H. Foulger R. Poux S. Lomax J. Bougueleret L. Xenarios I. Le Mercier P. The ins and outs of eukaryotic viruses: Knowledge base and ontology of a viral infection PLoS ONE 2017 12 e0171746 10.1371/journal.pone.0171746 28207819 PMC5313201 · DOI
  50. [52]Duerkop B.A. Hooper L.V. Resident viruses and their interactions with the immune system Nat. Immunol. 2013 14 654 659 10.1038/ni.2614 23778792 PMC3760236 · DOI
  51. [53]Volcy K. Dewhurst S. Proteasome inhibitors enhance bacteriophage lambda (lambda) mediated gene transfer in mammalian cells Virology 2009 384 77 87 10.1016/j.virol.2008.11.019 19064273 PMC2654414 · DOI
  52. [54]Przystal J.M. Umukoro E. Stoneham C.A. Yata T. O’Neill K. Syed N. Hajitou A. Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage Mol. Oncol. 2013 7 55 66 10.1016/j.molonc.2012.08.001 22951279 PMC3553581 · DOI
  53. [55]Tsafa E. Al-Bahrani M. Bentayebi K. Przystal J. Suwan K. Hajitou A. The natural dietary genistein boosts bacteriophage-mediated cancer cell killing by improving phage-targeted tumor cell transduction Oncotarget 2016 7 52135 52149 10.18632/oncotarget.10662 27437775 PMC5239540 · DOI
  54. [56]Fay N. Pante N. Nuclear entry of DNA viruses Front. Microbiol. 2015 6 467 10.3389/fmicb.2015.00467 26029198 PMC4429625 · DOI
  55. [57]Redrejo-Rodriguez M. Munoz-Espin D. Holguera I. Mencia M. Salas M. Functional eukaryotic nuclear localization signals are widespread in terminal proteins of bacteriophages Proc. Natl. Acad. Sci. USA 2012 109 18482 18487 10.1073/pnas.1216635109 23091024 PMC3494942 · DOI
  56. [58]Redrejo-Rodriguez M. Salas M. Multiple roles of genome-attached bacteriophage terminal proteins Virology 2014 468–470 322 329 10.1016/j.virol.2014.08.003 25232661 · DOI
  57. [59]Merril C.R. Geier M.R. Petricciani J.C. Bacterial virus gene expression in human cells Nature 1971 233 398 400 10.1038/233398a0 4940436 · DOI
  58. [60]Bentancor L.V. Bilen M.F. Mejías M.P. Fernández-Brando R.J. Panek C.A. Ramos M.V. Fernandez G.C. Isturiz M. Ghiringhelli P.D. Palermo M.S. Functional capacity of Shiga-toxin promoter sequences in eukaryotic cells PLoS ONE 2013 8 e57128 10.1371/journal.pone.0057128 23451160 PMC3579788 · DOI
  59. [61]Sanmukh S.G. dos Santos N.J. Barquilha C.N. Cucielo M.S. de Carvalho M. dos Reis P.P. Delella F.K. Carvalho H.F. Felisbino S.L. Bacteriophages M13 and T4 Increase the Expression of Anchorage-Dependent Survival Pathway Genes and Down Regulate Androgen Receptor Expression in LNCaP Prostate Cell Line Viruses 2021 13 1754 10.3390/v13091754 34578333 PMC8473360 · DOI
  60. [63]Smith G.P. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface Science 1985 228 1315 1317 10.1126/science.4001944 4001944 · DOI · Paper page
  61. [64]Haq I.U. Chaudhry W.N. Akhtar M.N. Andleeb S. Qadri I. Bacteriophages and their implications on future biotechnology: A review Virol. J. 2012 9 9 10.1186/1743-422X-9-9 22234269 PMC3398332 · DOI
  62. [65]Pande J. Szewczyk M.M. Grover A.K. Phage display: Concept, innovations, applications and future Biotechnol. Adv. 2010 28 849 858 10.1016/j.biotechadv.2010.07.004 20659548 · DOI · Paper page
  63. [66]Rakonjac J. Russel M. Khanum S. Brooke S.J. Rajic M. Filamentous Phage: Structure and Biology Adv. Exp. Med. Biol. 2017 1053 1 20 10.1007/978-3-319-72077-7_1 29549632 · DOI
  64. [67]Petrenko V.A. Landscape Phage: Evolution from Phage Display to Nanobiotechnology Viruses 2018 10 311 10.3390/v10060311 29880747 PMC6024655 · DOI
  65. [68]Tan Y. Tian T. Liu W. Zhu Z. Yang C.J. Advance in phage display technology for bioanalysis Biotechnol. J. 2016 11 732 745 10.1002/biot.201500458 27061133 · DOI
  66. [70]Zuo S. Dai G. Wang L. Wen Y. Huang Z. Yang W. Ma W. Ren X. Suppression of angiogenesis and tumor growth by recombinant T4 phages displaying extracellular domain of vascular endothelial growth factor receptor 2 Arch. Virol. 2019 164 69 82 10.1007/s00705-018-4026-0 30259141 · DOI
  67. [71]Aghebati-Maleki L. Bakhshinejad B. Baradaran B. Motallebnezhad M. Aghebati-Maleki A. Nickho H. Yousefi M. Majidi J. Phage display as a promising approach for vaccine development J. Biomed. Sci. 2016 23 66 10.1186/s12929-016-0285-9 27680328 PMC5041315 · DOI
  68. [72]Wang J. Lamolinara A. Conti L. Giangrossi M. Cui L. Morelli M.B. Amantini C. Falconi M. Bartolacci C. Andreani C. HER2-Displaying M13 Bacteriophages induce Therapeutic Immunity against Breast Cancer Cancers 2022 14 4054 10.3390/cancers14164054 36011047 PMC9406369 · DOI · Paper page
  69. [73]Iwagami Y. Casulli S. Nagaoka K. Kim M. Carlson R.I. Ogawa K. Lebowitz M.S. Fuller S. Biswas B. Stewart S. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma Heliyon 2017 3 e00407 10.1016/j.heliyon.2017.e00407 28971150 PMC5619992 · DOI
  70. [74]Hajitou A. Trepel M. Lilley C.E. Soghomonyan S. Alauddin M.M. Marini F.C. Restel B.H. Ozawa M.G. Moya C.A. Rangel R. A hybrid vector for ligand-directed tumor targeting and molecular imaging Cell 2006 125 385 398 10.1016/j.cell.2006.02.042 16630824 · DOI
  71. [75]Trepel M. Stoneham C.A. Eleftherohorinou H. Mazarakis N.D. Pasqualini R. Arap W. Hajitou A. A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer Mol. Cancer Ther. 2009 8 2383 2391 10.1158/1535-7163.MCT-09-0110 19671758 PMC2871293 · DOI
  72. [76]Smith T.L. Yuan Z. Cardó-Vila M. Claros C.S. Adem A. Cui M.-H. Branch C.A. Gelovani J.G. Libutti S.K. Sidman R.L. AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas Proc. Natl. Acad. Sci. USA 2016 113 2466 2471 10.1073/pnas.1525709113 26884209 PMC4780640 · DOI
  73. [77]Tandle A. Hanna E. Lorang D. Hajitou A. Moya C.A. Pasqualini R. Arap W. Adem A. Starker E. Hewitt S. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha Cancer 2009 115 128 139 10.1002/cncr.24001 19090007 PMC8385542 · DOI
  74. [78]Chongchai A. Waramit S. Suwan K. Al-Bahrani M. Udomruk S. Phitak T. Kongtawelert P. Pothacharoen P. Hajitou A. Bacteriophage-mediated therapy of chondrosarcoma by selective delivery of the tumor necrosis factor alpha (TNFalpha) gene FASEB J. 2021 35 e21487 10.1096/fj.202002539R 33811705 · DOI
  75. [79]Yang Zhou J. Suwan K. Hajitou A. Initial Steps for the Development of a Phage-Mediated Gene Replacement Therapy Using CRISPR-Cas9 Technology J. Clin. Med. 2020 9 1498 10.3390/jcm9051498 32429407 PMC7290871 · DOI
  76. [80]Asavarut P. Waramit S. Suwan K. Marais G.J.K. Chongchai A. Benjathummarak S. Al-Bahrani M. Vila-Gomez P. Williams M. Kongtawelert P. Systemically targeted cancer immunotherapy and gene delivery using transmorphic particles EMBO Mol. Med. 2022 14 e15418 10.15252/emmm.202115418 35758207 PMC9358398 · DOI
  77. [81]Hwang Y.J. Myung H. Engineered Bacteriophage T7 as a Potent Anticancer Agent in vivo Front. Microbiol. 2020 11 491001 10.3389/fmicb.2020.491001 33072000 PMC7541933 · DOI · Paper page
  78. [82]Yue H. Li Y. Yang M. Mao C. T7 Phage as an Emerging Nanobiomaterial with Genetically Tunable Target Specificity Adv. Sci. 2022 9 2103645 10.1002/advs.202103645 PMC8811829 34914854 · DOI
  79. [83]Kaufmann K.B. Buning H. Galy A. Schambach A. Grez M. Gene therapy on the move EMBO Mol. Med. 2013 5 1642 1661 10.1002/emmm.201202287 24106209 PMC3840483 · DOI
  80. [84]Ramamoorth M. Narvekar A. Non viral vectors in gene therapy- an overview J. Clin. Diagn. Res. 2015 9 GE01 GE06 10.7860/JCDR/2015/10443.5394 PMC4347098 25738007 · DOI
  81. [85]Larocca D. Kassner P.D. Witte A. Ladner R.C. Pierce G.F. Baird A. Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage FASEB J. 1999 13 727 734 10.1096/fasebj.13.6.727 10094933 · DOI
  82. [86]Larocca D. Jensen-Pergakes K. Burg M.A. Baird A. Receptor-targeted gene delivery using multivalent phagemid particles Mol. Ther. 2001 3 476 484 10.1006/mthe.2001.0284 11319907 · DOI
  83. [87]Hood J.D. Bednarski M. Frausto R. Guccione S. Reisfeld R.A. Xiang R. Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature Science 2002 296 2404 2407 10.1126/science.1070200 12089446 · DOI
  84. [88]Hajitou A. Lev D.C. Hannay J.A.F. Korchin B. Staquicini F.I. Soghomonyan S. Alauddin M.M. Benjamin R.S. Pollock R.E. Gelovani J.G. A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging Proc. Natl. Acad. Sci. USA 2008 105 4471 4476 10.1073/pnas.0712184105 18337507 PMC2393798 · DOI
  85. [89]Kia A. Przystal J.M. Nianiaris N. Mazarakis N.D. Mintz P.J. Hajitou A. Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression Mol. Cancer Ther. 2012 11 2566 2577 10.1158/1535-7163.MCT-12-0587 23053496 PMC3521030 · DOI
  86. [90]Chen C.-Y. Chang Y.-N. Ryan P. Linscott M. McGarrity G.J. Chiang Y.L. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the “bystander effect” Hum. Gene Ther. 1995 6 1467 1476 10.1089/hum.1995.6.11-1467 8573619 · DOI
  87. [91]Sadeghi H. Hitt M.M. Transcriptionally targeted adenovirus vectors Curr. Gene Ther. 2005 5 411 427 10.2174/1566523054546189 16101515 · DOI
  88. [92]Li J. Lee A.S. Stress induction of GRP78/BiP and its role in cancer Curr. Mol. Med. 2006 6 45 54 10.2174/156652406775574523 16472112 · DOI
  89. [93]Przystal J.M. Waramit S. Pranjol Z.I. Yan W. Chu G. Chongchai A. Samarth G. Olaciregui N.G. Tabatabai G. Carcaboso A.M. Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma EMBO Mol. Med. 2019 11 e8492 10.15252/emmm.201708492 30808679 PMC6460351 · DOI
  90. [94]Pfaffenbach K.T. Lee A.S. The critical role of GRP78 in physiologic and pathologic stress Curr. Opin. Cell Biol. 2011 23 150 156 10.1016/j.ceb.2010.09.007 20970977 PMC3043145 · DOI
  91. [95]Stoneham C.A. Hollinshead M. Hajitou A. Clathrin-mediated endocytosis and subsequent endo-lysosomal trafficking of adeno-associated virus/phage J. Biol. Chem. 2012 287 35849 35859 10.1074/jbc.M112.369389 22915587 PMC3476254 · DOI
  92. [96]Yata T. Lee E.L.Q. Suwan K. Syed N. Asavarut P. Hajitou A. Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors Mol. Cancer 2015 14 110 10.1186/s12943-015-0383-4 26037383 PMC4451735 · DOI
  93. [97]Yata T. Lee K.-Y. Dharakul T. Songsivilai S. Bismarck A. Mintz P.J. Hajitou A. Hybrid Nanomaterial Complexes for Advanced Phage-guided Gene Delivery Mol. Ther. Nucleic Acids 2014 3 e185 10.1038/mtna.2014.37 25118171 PMC4221597 · DOI
  94. [98]Suwan K. Yata T. Waramit S. Przystal J.M. Stoneham C.A. Bentayebi K. Asavarut P. Chongchai A. Pothachareon P. Lee K.-Y. Next-generation of targeted AAVP vectors for systemic transgene delivery against cancer Proc. Natl. Acad. Sci. USA 2019 116 18571 18577 10.1073/pnas.1906653116 31375630 PMC6744886 · DOI
  95. [99]Josephs S.F. Ichim T.E. Prince S.M. Kesari S. Marincola F.M. Escobedo A.R. Jafri A. Unleashing endogenous TNF-alpha as a cancer immunotherapeutic J. Transl. Med. 2018 16 242 10.1186/s12967-018-1611-7 30170620 PMC6119315 · DOI
  96. [100]Paoloni M.C. Tandle A. Mazcko C. Hanna E. Kachala S. Leblanc A. Newman S. Vail D. Henry C. Thamm D. Launching a novel preclinical infrastructure: Comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature PLoS ONE 2009 4 e4972 10.1371/journal.pone.0004972 19330034 PMC2659423 · DOI
  97. [101]Staquicini F.I. Smith T.L. Tang F.H.F. Gelovani J.G. Giordano R.J. Libutti S.K. Sidman R.L. Cavenee W.K. Arap W. Pasqualini R. Targeted AAVP-based therapy in a mouse model of human glioblastoma: A comparison of cytotoxic versus suicide gene delivery strategies Cancer Gene Ther. 2020 27 301 310 10.1038/s41417-019-0101-2 31130731 PMC6879804 · DOI
  98. [102]Duffy M.J. Synnott N.C. Crown J. Mutant p53 as a target for cancer treatment Eur. J. Cancer 2017 83 258 265 10.1016/j.ejca.2017.06.023 28756138 · DOI
  99. [103]Zhu J. Tao P. Mahalingam M. Sha J. Kilgore P. Chopra A.K. Rao V. A prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells Sci. Adv. 2019 5 eaax0064l 10.1126/sciadv.aax0064 31457098 PMC6703872 · DOI
  100. [104]Xu H. Bao X. Wang Y. Xu Y. Deng B. Lu Y. Hou J. Engineering T7 bacteriophage as a potential DNA vaccine targeting delivery vector Virol. J. 2018 15 49 10.1186/s12985-018-0955-1 29558962 PMC5859711 · DOI
  101. [105]Sun W. Shi Q. Zhang H. Yang K. Ke Y. Wang Y. Qiao L. Advances in the techniques and methodologies of cancer gene therapy Discov. Med. 2019 27 45 55 30721651
  102. [106]Santiago-Ortiz J.L. Schaffer D.V. Adeno-associated virus (AAV) vectors in cancer gene therapy J. Control. Release 2016 240 287 301 10.1016/j.jconrel.2016.01.001 26796040 PMC4940329 · DOI
  103. [107]Sagona A.P. Grigonyte A.M. MacDonald P.R. Jaramillo A. Genetically modified bacteriophages Integr. Biol. 2016 8 465 474 10.1039/C5IB00267B 26906932 · DOI
  104. [108]Pranjol M.Z. Hajitou A. Bacteriophage-derived vectors for targeted cancer gene therapy Viruses 2015 7 268 284 10.3390/v7010268 25606974 PMC4306838 · DOI
  105. [109]Lankes H. Zanghi C. Santos K. Capella C. Duke C. Dewhurst S. In vivo gene delivery and expression by bacteriophage lambda vectors J. Appl. Microbiol. 2007 102 1337 1349 10.1111/j.1365-2672.2006.03182.x 17448169 PMC2063594 · DOI

Cited by

Sorted by citations

Authors
Petrov, G., Dymova, M., & Richter, V.
Affiliations
Institute of Chemical Biology and Fundamental Medicine (RU)
Corresponding author
Dymova, Maya
ORCID
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-11-17
Volume
23
Issue
22
Pages
14245
ISSN
1422-0067 (ISSN-L)
DOI
10.3390/ijms232214245
PMC
PMC9697857
OpenAlex
W4309463299
Cited by
38
References
3
Citations by year
2026: 12 · 2025: 9 · 2024: 10 · 2023: 7
FWCI
0.60
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Russian State-funded budget project of ICBFM SB RAS (121030200173-6)
Topics
  • Physical Sciences › Environmental Science › Ecology › Bacteriophages and microbial interactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
bacteriophages, cancer gene therapy, transgene delivery, targeted gene delivery, phage engineering, systemic drug delivery
MeSH terms
Animals, Bacteriophages, Pharmaceutical Preparations, Mammals, Neoplasms, Genetic Therapy, Gene Transfer Techniques, Genes, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review